Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL579041 | 0.85 | SLC6A4 (0.56) | SLC6A4TAAR1SLC6A2SLC6A3 | |
| SCHEMBL1679320 | 0.84 | SLC7A5 (0.56) | PTGS2SLC6A3 | |
| SCHEMBL6251835 | 0.84 | SLC6A4 (0.56) | SLC6A4PTGS2TAAR1SLC6A2SLC6A3 | |
| SCHEMBL27293364 | 0.82 | SLC6A4 (0.61) | SLC6A4TAAR1SLC6A2SLC6A3 | |
| SCHEMBL578977 | 0.81 | ITGB3 (0.48) | SLC6A4PTGS2TAAR1SLC6A2SLC6A3 | |
| SCHEMBL16124569 | 0.81 | THRB (0.54) | PTGS2 | |
| SCHEMBL28506588 | 0.80 | SLC6A4 (0.59) | SLC6A4TAAR1SLC6A2SLC6A3 | |
| SCHEMBL157109 | 0.80 | SLC6A4 (0.59) | SLC6A4TAAR1SLC6A2SLC6A3 | |
| SCHEMBL21464418 | 0.80 | SLC6A4 (0.59) | SLC6A4TAAR1SLC6A2SLC6A3 | |
| SCHEMBL14478245 | 0.80 | SLC6A4 (0.59) | SLC6A4TAAR1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644019-B2 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | SHIRE LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| CN-1816346-B | Abuse resistant amphetamine compounds | SHIRE LLC | 2013-04-17 | — | — | CN | disclosed |
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2012-05-10 | — | — | US | disclosed |
| EP-1644019-B1 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | SHIRE LLC (US) | 2012-02-15 | — | — | EP | disclosed |
| CN-1925865-B | Pharmaceutical compositions for prevention of overdose or abuse | SHIRE LLC | 2011-09-14 | — | — | CN | disclosed |
| US-20110009669-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-7723305-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7718619-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-18 | — | — | US | disclosed |
| US-7713936-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-11 | — | — | US | disclosed |
| WO-2006121552-A2 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| US-7105486-B2 | Administering L-lysine-d-amphetamine; attention deficit hyperactivity disorder; decreasing the bioavailability of amphetamine by intravenous or intranasal administration, further limiting their abuse liability. | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-09-12 | — | — | US | disclosed |
| CN-1816346-A | Abuse resistant amphetamine compounds | NEW RIVER PHARMACEUTICALS INC (US) | 2006-08-09 | — | — | CN | disclosed |
| EP-1675555-A2 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF OVERDOSE OR ABUSE | New River Pharmaceuticals Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-1644019-A1 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | New River Pharmaceuticals Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050176646-A1 | Covalently bonding a narcotic to a single amino acid or an oligopeptide of 15 or fewer amino acids such that the narcotic does not release into a patient's bloodstream at levels that give rise to a euphoric or overdose level | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005032474-A2 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF OVERDOSE OR ABUSE | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050054561-A1 | Abuse-resistant amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
| US-20050038121-A1 | Abuse resistant lysine amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005000334-A1 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | NEW RIVER PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054561-A1 | Abuse-resistant amphetamine compounds | COMT, CYP3A5, SLC6A2 | SLC6A4 25/4885PTGS2 4687/4885TAAR1 118/4885 |
| US-20050038121-A1 | Abuse resistant lysine amphetamine compounds | COMT, KDM6B, KDM5B | SLC6A4 67/4885PTGS2 4788/4885TAAR1 255/4885 |
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A4 41/4885PTGS2 4584/4885TAAR1 161/4885 |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A4 41/4885PTGS2 4584/4885TAAR1 161/4885 |
| US-20050176646-A1 | Covalently bonding a narcotic to a single amino acid or an oligopeptide of 15 or fewer amino acids such that the narcotic does not release into a patient's bloodstream at levels that give rise to a euphoric or overdose level | DNPEP, OGFR, OPRL1 | SLC6A4 155/4885PTGS2 3165/4885TAAR1 244/4885 |
| US-20110009669-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A4 41/4885PTGS2 4584/4885TAAR1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.